₨ 6,000
Safacto AF 500 IU is a medication used to treat and prevent bleeding in patients with hemophilia A, which is a congenital factor VIII deficiency. The medication contains moroctocog alfa, which is a recombinant human coagulation factor VIII. It works by replacing the missing factor VIII in the body to help the blood clot.
Key Information
- Purpose: SaFacto AF is used for the control, prevention, and routine prophylaxis of bleeding episodes in adults and children with Hemophilia A, which is a congenital factor VIII deficiency. It is also used for the management of bleeding during surgical procedures.
- Mechanism of Action: The medication is produced using recombinant DNA technology and acts similarly to the coagulation factor VIII protein that is deficient in patients with Hemophilia A. By replacing this missing factor, it helps the blood to clot and provides temporary control of bleeding.
- Dosage: The dosage and duration of treatment depend on the severity of the deficiency, the location and extent of the bleeding, and the patient's clinical condition. It is administered intravenously after reconstitution with the provided solvent.
- Manufacturer: Saman Daroo 8 is an Iranian biotechnology company that is the first and only manufacturer of recombinant factor VIII in Iran. The company produced this drug in 2015, and it entered the Iranian market in 2016.
Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for diagnosis, treatment, and any medical-related questions.
₨ 10,000
